
Opinion|Podcasts|October 31, 2023
Achieving Superior Treatment Durability and Outcomes in Neovascular AMD and DME
Listen
0:00 / 0:00
Expert retina specialists discuss the latest therapies that could reduce the treatment burden and provide superior clinical outcomes in retinal diseases.
Advertisement
0:00 Introduction
0:52 Need for durable treatments in nAMD and DME
4:20 Mechanism of faricimab
7:10 Highlights from clinical trials for faricimab
10:28 Post hoc analyses of faricimab clinical trials
16:19 Factors affecting retreatment decision
19:20 Durability data for faricimab
23:22 Experience with faricimab
29:00 Choosing between faricimab and high-dose aflibercept
32:47 Final remarks
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
AIRCULES: Lunsekimig Benefit Scales With Severity, With Njira Lugogo, MD
2
What Baseline Disease Severity Hides in PsA Trial Data, With David Oberlin, MD
3
KT-621 Achieves Deep STAT6 Degradation, Initial Respiratory, Skin Gains
4
ESC 2026 Recap: 5 Practice-Changing Trials to Know
5






























































